137 related articles for article (PubMed ID: 32880003)
1. The survival and prognosis analysis of synovial sarcoma subtypes: a Surveillance, Epidemiology, and End Results population-based analysis.
Xiong L; Chen Z; Zhou Y; Li H; Xiao T
Int Orthop; 2020 Dec; 44(12):2779-2786. PubMed ID: 32880003
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis.
Aytekin MN; Öztürk R; Amer K; Yapar A
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020936009. PubMed ID: 32618221
[TBL] [Abstract][Full Text] [Related]
3. Synovial Sarcoma Is Not Associated With a Higher Risk of Lymph Node Metastasis Compared With Other Soft Tissue Sarcomas.
Jacobs AJ; Morris CD; Levin AS
Clin Orthop Relat Res; 2018 Mar; 476(3):589-598. PubMed ID: 29529647
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Survival in Patients With Synovial Cell Sarcoma of the Head and Neck: An Analysis of 167 Cases Using the SEER (Surveillance, Epidemiology, and End Results) Database.
Mallen-St Clair J; Arshi A; Abemayor E; St John M
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):576-83. PubMed ID: 27100936
[TBL] [Abstract][Full Text] [Related]
5. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients.
Sultan I; Rodriguez-Galindo C; Saab R; Yasir S; Casanova M; Ferrari A
Cancer; 2009 Aug; 115(15):3537-47. PubMed ID: 19514087
[TBL] [Abstract][Full Text] [Related]
6. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression.
ten Heuvel SE; Hoekstra HJ; Bastiaannet E; Suurmeijer AJ
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):189-95. PubMed ID: 18997619
[TBL] [Abstract][Full Text] [Related]
7. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.
Kawai A; Woodruff J; Healey JH; Brennan MF; Antonescu CR; Ladanyi M
N Engl J Med; 1998 Jan; 338(3):153-60. PubMed ID: 9428816
[TBL] [Abstract][Full Text] [Related]
8. Synovial sarcoma. A Scandinavian Sarcoma Group project.
Skytting B
Acta Orthop Scand Suppl; 2000 Apr; 291():1-28. PubMed ID: 10862210
[TBL] [Abstract][Full Text] [Related]
9. The Role of Surgery for Primary Pulmonary Synovial Sarcoma: A Population-Based Study.
Chen X; Ma G; Zhao X; Liu J; Li J; Du J
J Surg Res; 2022 Nov; 279():338-351. PubMed ID: 35810551
[TBL] [Abstract][Full Text] [Related]
10. Multivariate analysis of prognostic factors in synovial sarcoma.
Koh KH; Cho EY; Kim DW; Seo SW
Orthopedics; 2009 Nov; 32(11):824. PubMed ID: 19902890
[TBL] [Abstract][Full Text] [Related]
11. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Kawai A; Sonobe H; Takahira T; Kobayashi C; Yamamoto H; Tamiya S; Hirohashi S; Iwamoto Y; Tsuneyoshi M
Am J Surg Pathol; 2007 Jan; 31(1):85-94. PubMed ID: 17197923
[TBL] [Abstract][Full Text] [Related]
12. Derivation and validation of a risk classification tree for patients with synovial sarcoma.
Neel DV; Ma C; Collins NB; Hornick JL; Demetri GD; Shulman DS
Cancer Med; 2023 Jan; 12(1):170-178. PubMed ID: 35670308
[TBL] [Abstract][Full Text] [Related]
13. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
14. Nonrhabdomyosarcoma soft tissue sarcomas in children: is age at diagnosis an important variable?
Hayes-Jordan AA; Spunt SL; Poquette CA; Cain AM; Rao BN; Pappo AS; Shochat SJ
J Pediatr Surg; 2000 Jun; 35(6):948-53; discussion 953-4. PubMed ID: 10873042
[TBL] [Abstract][Full Text] [Related]
15. Treatment of limb synovial sarcoma with metastasis at presentation.
Guo P; Zhao R; Zhou Y; Shen Y
Medicine (Baltimore); 2020 Jun; 99(23):e20550. PubMed ID: 32502019
[TBL] [Abstract][Full Text] [Related]
16. Synovial sarcoma of the abdominal wall.
Fetsch JF; Meis JM
Cancer; 1993 Jul; 72(2):469-77. PubMed ID: 8391380
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of conditional treatment effects of adjuvant treatments on patients with synovial sarcoma using Bayesian subgroup analysis.
Seo SW; Kim J; Son J; Lim S
BMC Med Inform Decis Mak; 2020 Dec; 20(1):320. PubMed ID: 33272256
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan.
Takenaka S; Ueda T; Naka N; Araki N; Hashimoto N; Myoui A; Ozaki T; Nakayama T; Toguchida J; Tanaka K; Iwamoto Y; Matsumine A; Uchida A; Ieguchi M; Kaya M; Wada T; Baba I; Kudawara I; Aoki Y; Yoshikawa H
Oncol Rep; 2008 Feb; 19(2):467-76. PubMed ID: 18202796
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features.
Saito T; Oda Y; Sugimachi K; Kawaguchi K; Tamiya S; Tanaka K; Matsuda S; Sakamoto A; Iwamoto Y; Tsuneyoshi M
Am J Pathol; 2001 Dec; 159(6):2117-24. PubMed ID: 11733362
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic factors and adjuvant treatment effects on survival in adult head and neck synovial cell sarcoma.
Crowson MG; Lalich I; Keeney MG; Garcia JJ; Price DL
Head Neck; 2015 Mar; 37(3):375-80. PubMed ID: 24430934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
